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At a false-positive rate (FPR) of 5%, specificity for R5-tropic virus was also high
(range: 85.7%-95.3%), but came at the expense of sensitivity for X4-using virus
(range: 36.7%-66.7%). One study compared the effectiveness of both genotypic tro-
pism testing and ESTA in predicting virological response to the CCR5-antagonist
maraviroc. The study found in each screening group, a similar proportion of pa-
tients achieved a viral load 50 HIV-1 RNA copies/mL byWeek 48. CONCLUSIONS:
In the absence of a ‘gold standard’, clinical response to CCR5-anatagonist therapy offers
the bestmeasure of diagnostic performance in HIV-1 tropism testing. The results of this
review indicate that genotypic sequencing of the V3 loop is as capable of predicting re-
sponse toCCR5-antagonist therapyas the currentdiagnostic standard, ESTA. Inaddition,
of the bioinformatic algorithms reviewed here, the geno2pheno model set at 5-10% FPR
offered the best balance between sensitivity and specificity. This evidence provides fur-
ther support for the use of genotypic tropism testing in routine clinical practice.
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OBJECTIVES: To evaluate the relationship between vancomycin trough concentra-
tion and the clinical outcome in hospitalized patients with ORSA bacteremia, and
to assess the relationship between vancomycin trough concentration and
nephrotoxicity. METHODS: Adult patients admitted to National Cheng-Kung Uni-
versity Hospital during January 20, 2006 and July 31, 2006 and treated with vanco-
mycin for ORSA bacteremia were eligible for this prospective observational study.
On the fourth day after vancomycin use, vancomycin concentration was moni-
tored and blood culture was repeated. Regular biochemistry and blood test on day
4, 7, 11, 14, daily highest temperatue and other associated data were collected. The
primary endpoints are the clinical outcome and the change of serum creatinine
concentration. RESULTS: Nineteen patients were enrolled during this period. On
day 4, trough concentration of vancomycin was associated with the rate of defer-
vescence. The afebrile rate were 85.7% and 33.3% among patients with trough level
of above and below 15 g/mL, respectively (P  0.05). For the ratio of vancomycin
trough concentration to MIC, patients with ratio greater than 10 had a trend of a
higher defervescence rate in comparison with those with ratio less than 10 (77.8%
vs. 30%, P  0.07). In addition, nephrotoxicity was found in five patients, but the
mean trough concentrations were not significantly different between the nephro-
toxic and non-nephrotoxic groups. CONCLUSIONS: The result of the study shows
that higher serum vancomycin trough concentration is associated with the defer-
vescence rate on day 4 when vancomycin is used to treat ORSA bacteremia. Be-
sides, under the condition of regular therapeutic drug monitoring, the nephrotox-
icity during vancomycin therapy doesn’t seem to be associated with trough
concentration, but it needs studies with large sample size to evaluate.
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OBJECTIVES: Large antimicrobial consumption in intensive care units (ICUs) con-
tributes heavy health care burden in Taiwan. This study evaluates the short term
influence of pharmacist-led antimicrobial stewardship (PLAS) in ICUs.METHODS:
A prospective PLAS program was implemented in medical and surgical ICUs, in-
cluding dose optimization (renal dose monitoring and therapeutic drug monitor-
ing), streamlining or de-escalation of therapy, antimicrobial order forms, and an-
timicrobial treatment duration review, which any antimicrobial duration over
7days was reviewed. Data collection was from October 19, 2011 to December 2,
2011. Patients who admitted to ICU and received at least one parenteral antimicro-
bial were included. Outcomes included suggestion implementation rate of phar-
macist interventions and cost that saving from dose optimization. Feedbacks of
non-accepted suggestions were also addressed. RESULTS: Sixty-two (21%) of study
population received 88 suggestions. Sixty-two (70.5%) suggestions were imple-
mented. Themajority of suggestions is duration review (30.7%) followed by stream-
lining or de-escalation of therapy (30.6%) and dose optimization (27.3%). There was
76,238 NTDs saving from renal dose monitoring. Further efforts we can make are
found from reasons of non-accepted suggestion. For example, education on pro-
phylactic antibiotics and antimicrobial renal dosage adjustment should be
provided. Since, we found that prolonged (3days) post-operation antimicrobial
prophylaxis until inserted drainage lumen removed and refusing dose increasing
because impaired renal function was expected by doctors. Involvement in multi-
disciplinary specialists is required due to denials from no recommendation from
infectious disease physicians. CONCLUSIONS: A PLAS efforts rationale antimicro-
bial utilization and leads to potential reduction in both the incidence of adverse
effects and the burden of health care. Through feedback from refused suggestion,
however, we found that antimicrobial stewardship should include a multidisci-
plinary team, especially incorporating with infectious disease physicians.
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OBJECTIVES: The optimal timing of initiation of Antiretroviral Therapy (ART) in
ART naïve patients with HIV and TB co-infection remains inconclusive. IRIS inci-
dence is one of the most important outcomes that we need to consider when
making a decision on the time of initiating ART. This study compared the IRIS
incidence in patients initiating ART earlier (2 months after the start of tubercu-
losis therapy) versus later (2 months after the start of tuberculosis therapy). We
also examined the differences of IRIS incidence between early and late arms in the
Resources limited settings (RLS) and the Non Resources limited settings (NRLS).
METHODS:Data for this meta-analysis were extracted from Pubmed/Medline, Em-
base, Cochrane database of systematic review, Cochrane Central Register of Con-
trolled Trials, International Pharmaceutical Abstracts, ClinicalTrials.gov and
Google Scholar from year 1986 to 2011. We searched by using a combination of
terms: HIV, HIV infections, acquired immunodeficiency syndrome, tuberculosis,
TB, HAART, highly active antiretroviral therapy, ART, antiretroviral therapy. Out of
the 11300 studies found in the search, five cohort studiesmet the inclusion criteria.
Among the five studies, two were located in RLS and three were located in NRLS.
We conducted a meta-analysis of these five studies by using STATA SE version 12.
RESULTS:Meta-analysis results showed that overall, people treated with ART ear-
lier during TB therapy had a 12.9% lower risk of IRIS incidence compared to people
treated later (RR, 0.871; 95% CI, 0.831-0.912). In addition, the differences of IRIS
incidence between early and late arms were significant in both the Resources lim-
ited settings (RLS) and the Non Resources limited settings (NRLS). CONCLUSIONS:
Initiating antiretroviral therapy less than 2 months after the start of tuberculosis
therapy is associated with a significantly lower risk of IRIS incidence, regardless of
the locations.
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OBJECTIVES: To report clinical burden of Japanese encephalitis (JE) in Asia and
cost-effectiveness of JE vaccination program. METHODS: Systematic literature
searches were conducted using Embase®, MEDLINE®, WHO, and Google scholar
platforms to identify relevant studies in patients with JE. Eligibility of trials was
assessed by two reviewerswith any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 10 studies out of 41 retrieved, met the inclusion
criteria for the clinical review. Approximately 35,000-50,000 JE cases and 10,000–
15,000 deaths due to JE were reported every year in Asia. Incidence of JE was high in
China and India, with China accounting for 50% of the JE cases reportedworldwide.
The incidence of JE in China was reported to be 0.01-1.53 residents/year/100,000.
The number of JE cases reported in China, India, Nepal, Sri Lanka, and Bangladesh
were 5,000-10,000, 1,500-4,000, 1,000-3,000, 100-200, and 56, respectively. JE caused
12,038 and 2,496 deaths in Southeast Asia andWestern Pacific, respectively (2008).
JE was associated with 491,797 disability-adjusted life years (DALYs) in the South-
east Asia and 185,573 DALYs in the Western Pacific region (2004). Four studies out
of 59 retrieved, met the eligibility criteria for evaluating cost-effectiveness of JE
vaccination. JE vaccination prevented 117 cases and 12 deaths (Vietnam), 103 cases
and 18 deaths (Thailand), 420 cases and 105 deaths (China), and 175-316 cases and
36-65 deaths (India). Total savings in the direct medical costs witnessed as a con-
sequence of JE vaccination were $51,122 (Vietnam), $58,776 (Thailand), $614,762
(China), and $178,558-$319,627 (India). CONCLUSIONS: JE has lead to significant
morbidity in survivors and mortality in Asian countries. Existing evidence from
cost-effectiveness studies demonstrated that vaccination program markedly re-
duced the burden of JE in Asia.
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OBJECTIVES: To assess the incidence and distribution of infectious diseases which
have been markedly affected by climate change. METHODS: Literature searches
were performed using Embase®, MEDLINE®, Google Scholar, and WHO website.
RESULTS: Current evidence suggests that inter-annual and inter-decadal climate
variability have a direct impact on the epidemiology of infectious diseases. Accord-
ing to WHO, since mid-1970s, climatic changes have caused annually over 150 000
deaths and an approximately 5 million disability-adjusted life-years, mainly in
developing countries. Malaria has been considered as an extremely climate-sensi-
tive disease. A temperature rise of 2°C-3°C increases the risk of malaria by 3%-5%.
Across the world, the incidence cases of malaria increased from 233 000 in 2000 to
244 000 in 2005, with highest incidence observed in Africa. The West Nile virus
(WNV) disease is considered as an emerging epidemic in the US. More than 7000
neuroinvasiveWNV disease cases were reported in the US from 1999-2004. Parallel
to rising temperatures, the US has recorded a 41% increase in vibrio infection rate
from 1996-2006. In continental Europe, a temperature rise of 6°C above the mean
resulted in an estimated 30% reported cases of salmonellosis. In Russia, rising
temperatures from 2001 have increased the incidence of tick-borne encephalitis
(TBE) by 10-fold within a decade. Korea’s climatic variability has also been posi-
tively correlatedwith the incidence cases ofmalaria, Vibrio vulnificus sepsis, scrub
typhus, leptospirosis, and Hantavirus infection during 2001-2008. Further, in 2009-
2010, government officials of Europe have predicted that borreliosis, WNV fever,
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